CRISPR/Cas9-mediated knockout of APOC3 stabilizes plasma lipids and inhibits atherosclerosis in rabbits.

Yiwen ZhaYaoyao LuTing ZhangKunning YanWenwen ZhuangJingyan LiangYong ChengYingge Wang

Published in: Lipids in health and disease (2021)

APOC3 deficiency can delay the formation of atherosclerosis-induced HFD in rabbits, indicating this is a novel therapeutic target to treat atherosclerosis.

Keyphrases

crispr cas
cardiovascular disease
genome editing
high glucose
high fat diet
diabetic rats
type diabetes
fatty acid
skeletal muscle
insulin resistance
endothelial cells
replacement therapy
wild type